Trial Profile
A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide; Doxorubicin; Filgrastim; Lenograstim; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 24 Aug 2021 Results assessing safety and efficacy in patients with previously untreated DLBCL, grade 3B FL, or transformed lymphoma published in the Blood
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 1 Mar 2020 to 1 Feb 2020.